Lanzkowsky Manual of Pediatric Hematology and Oncology

5. Auflage 2005
ISBN: 978-0-12-375155-3
Verlag: Elsevier Science & Techn.
Format: EPUB
Kopierschutz: 6 - ePub Watermark

E-Book, Englisch, 1058 Seiten

Given that there have been considerable advances in the treatment and management of oncologic diseases in children, the fifth edition of this successful clinical manual will be entirely updated to incorporate all current protocols and developments.This edition will be a comprehensive book on patient management, replete with algorithms and flow diagrams on diagnosis and management. Its concise and easy-to-read format will enable readers to make accurate diagnoses and permit them to treat patients without having extensive previous hematologic/oncologic experience. A list of normal values at various ages in children, providing an extremely useful reference for patient management is included. - Selected for inclusion in Doody's Core Titles 2013, an essential collection development tool for health sciences libraries - Offers a concise, systematic approach to all pediatric hematologic and oncologic disorders in one reference manual - Easy-to-read format: multiple tables, charts, and flow-diagrams for diagnosis and management of pediatric hematologic and oncologic disorders - Clear presentation by practicing clinicians, who are also academic researchers, of recent developments in molecular genetics, cytogenetics, immunology, transplantation, and biochemistry

Autoren/Hrsg.

Lanzkowsky, Philip

Inhaltsverzeichnis

1;Front Cover;1
2;Manual of Pediatric Hematology and Oncology;4
3;Copyright Page;5
4;Contents;6
5;Dedication;8
6;Contributors;10
7;Introduction;16
8;Preface to the Fifth Edition;23
9;Preface to the Fourth Edition;25
10;Preface to the Third Edition;27
11;Preface to the Second Edition;29
12;Preface to the First Edition;30
13;Chapter 1. Classification and Diagnosis of Anemia in Children;32
13.1;Suggested Reading;44
14;Chapter 2. Anemia During the Neonatal Period;45
14.1;Hemorrhage;45
14.2;Hemolytic Anemia;50
14.3;Failure of Red Cell Production;64
14.4;Anemia of Prematurity;64
14.5;Physiologic Anemia;66
14.6;Diagnostic Approach to Anemia in the Newborn;66
14.7;Suggested Reading;68
15;Chapter 3. Iron-Deficiency Anemia;69
15.1;Prevalence;69
15.2;Etiologic Factors;69
15.3;Non-Hematological Manifestations;75
15.4;Diagnosis;75
15.5;Treatment;84
15.6;Suggested Reading;88
16;Chapter 4. Megaloblastic Anemia;89
16.1;Vitamin B[sub(12)] (Cobalamin) Deficiency;89
16.2;Folic Acid Deficiency;104
16.3;General Clinical Features of Cobalamin and Folate Deficiency;111
16.4;Diagnosis;112
16.5;Treatment;115
16.6;Suggested Reading;117
17;Chapter 5. Hematologic Manifestations of Systemic Illness;118
17.1;Hematologic Manifestations of Diseases of Various Organs;118
17.2;Chronic Illness;127
17.3;Lead Intoxication;140
17.4;Nutritional Disorders;140
17.5;Bone Marrow Infiltration;141
17.6;Suggested Reading;153
18;Chapter 6. Bone Marrow Failure;154
18.1;Aplastic Anemia;154
18.2;Acquired Aplastic Anemia;157
18.3;Congenital Aplastic Anemias;169
18.4;Dyskeratosis congenita;178
18.5;Congenital Aplastic Anemias of Unknown Inheritance;181
18.6;Diamond-Blackfan Anemia (Congenital Pure Red Cell Aplasia);182
18.7;Transient Erythroblastopenia;188
18.8;Congenital Dyserythropoietic Anemia (CDA);189
18.9;Sideroblastic Anemias (Mitochondrial Diseases with Bone Marrow Failure Syndromes);193
18.10;Suggested Reading;197
19;Chapter 7. Red Cell Membrane and Enzyme Defects;199
19.1;General Approach to Diagnosis of Hemolytic Anemia;199
19.2;Membrane Defects;203
19.3;Paroxysmal Nocturnal Hemogloginuria;216
19.4;Enzyme Defects;222
19.5;Suggested Reading;230
20;Chapter 8. Hemoglobinopathies;231
20.1;Sickle Cell Disease;231
20.2;Unstable Hemoglobins;261
20.3;Thalassemias;262
20.4;ß-Thalassemia: Homozygous or Doubly Heterozygous Forms (Major and Intermedia);265
20.5;ß-Thalassemia Intermedia;275
20.6;ß-Thalassemia Minor or Trait (Heterozygous ß[sup(0)] or ß+);276
20.7;a-Thalassemias;276
20.8;Suggested Reading;276
21;Chapter 9. Extracorpuscular Hemolytic Anemia;278
21.1;Immune Hemolytic Anemia;278
21.2;Nonimmune Hemolytic Anemia;285
21.3;Suggested Reading;287
22;Chapter 10. Polycythemia;288
22.1;Polycythemia (Erythrocytosis) in the Newborn;288
22.2;Polycythemia in Childhood;292
22.3;Polycythemia Vera;293
22.4;Primary Familial and Congenital Polycythemia;296
22.5;Congenital Polycythemia Due to Altered Hypoxia Sensing with Normal P50;297
22.6;Prolyl Hydroxylase Domain (PHD) 2 Mutations;299
22.7;Congenital Polycythemia Due to Altered Hypoxia Sensing with Decreased P50;299
22.8;Other Causes of Polycythemia;300
22.9;Diagnostic Approach;300
22.10;Suggested Reading;302
23;Chapter 11. Disorders of White Blood Cells;303
23.1;Quantitative Disorders of Leukocytes;303
23.2;Decreased Polymorphonuclear Leukocyte Production;309
23.3;Increased Destruction or Disorders of Distribution of Polymorphonuclear Leukocytes;320
23.4;Eosinophils;326
23.5;Lymphocytes;333
23.6;Neutrophil Production and Destruction in Newborn Infants;349
23.7;Suggested Reading;350
24;Chapter 12. Disorders of Platelets;352
24.1;Thrombocytopenia in the Newborn;352
24.2;Inherited Thrombocytopenias;366
24.3;Thrombocytopenia in Childhood;374
24.4;Thrombocytosis;390
24.5;Qualitative Platelet Disorders;393
24.6;Acquired Platelet Disorders;400
24.7;Inherited Vascular and Connective Tissue Disorders;403
24.8;Laboratory Evaluation of Platelets and Platelet Function;404
24.9;Nonthrombocytopenic Purpura;406
24.10;Suggested Reading;407
25;Chapter 13. Hemostatic Disorders;409
25.1;Physiology of Hemostasis;409
25.2;Fibrinolysis;413
25.3;Natural Inhibitors of Coagulation;414
25.4;Hemostasis in the Newborn;416
25.5;Detection of Hemostatic Defects;418
25.6;Acquired Coagulation Factor Disorders;421
25.7;Inherited Coagulation Factor Disorders;426
25.8;Rare Inherited Coagulation Factor Disorders (Factor II, V, VII, X, XIII, Fibrinogen Deficiencies);447
25.9;Hereditary Disorders of Platelet Function;448
25.10;Suggested Reading;449
26;Chapter 14. Thrombotic Disorders;450
26.1;Mechanisms of Thrombosis in Inherited Thrombophilia;450
26.2;Venous Thrombosis;450
26.3;Arterial Thrombosis;452
26.4;Antiphospholipid Syndrome;461
26.5;Hereditary Thrombotic Disorders;467
26.6;Thrombotic Disorders in Newborns;474
26.7;Antithrombotic Agents;476
26.8;Heparin-induced Thrombocytopenia;481
26.9;Thrombolytic Therapy;486
26.10;Antithrombotic Therapy in Special Conditions;489
26.11;Suggested Reading;491
27;Chapter 15. Lymphadenopathy and Splenomegaly;492
27.1;Lymphadenopathy;492
27.2;Splenomegaly;499
27.3;Suggested Reading;502
28;Chapter 16. Lymphoproliferative Disorders, Myelodysplastic Syndromes and Myeloproliferative Disorders;503
28.1;Lymphoproliferative Disorders;503
28.2;Myelodysplastic Syndrome;525
28.3;Juvenile Myelomonocytic Leukemia (JMML);534
28.4;Chronic Myeloproliferative Diseases;539
28.5;Chronic Myeloid Leukemia (CML);539
28.6;Suggested Reading;547
29;Chapter 17. Leukemias;549
29.1;Incidence;549
29.2;Etiology;549
29.3;Clinical Features of Acute Lymphoblastic Leukemia (ALL);550
29.4;Acute Myeloid Leukemia;581
29.5;Suggested Reading;595
30;Chapter 18. Histiocytosis Syndromes;598
30.1;Langerhans Cell Histiocytosis;598
30.2;Other Histiocytic Disorders;616
30.3;Dermal Dendrocyte Disorders;616
30.4;Suggested Reading;627
31;Chapter 19. Hodgkin Lymphoma;630
31.1;Etiology and Epidemiology;630
31.2;Risk Factors;630
31.3;Biology;631
31.4;Pathology;631
31.5;Clinical Presentation;634
31.6;Diagnostic Evaluation and Staging;638
31.7;Prognostic Factors;640
31.8;Treatment;642
31.9;Long-term Complications;648
31.10;Follow-up Evaluations;652
31.11;Suggested Reading;653
32;Chapter 20. Non-Hodgkin Lymphoma;655
32.1;Introduction;655
32.2;Incidence and Epidemiology;655
32.3;Pathologic Classification;656
32.4;Clinical Features;656
32.5;Diagnosis;661
32.6;Staging;661
32.7;Management;662
32.8;Lymphoblastic Lymphoma;663
32.9;B lineage NHL (BC, BLL and DLCL);664
32.10;Suggested Reading;676
33;Chapter 21. Central Nervous System Malignancies;678
33.1;Pathology;678
33.2;Clinical Manifestations;680
33.3;Diagnostic Evaluation;682
33.4;Treatment;685
33.5;Astrocytomas;688
33.6;Medulloblastoma;691
33.7;Brain Stem Tumors;694
33.8;Ependymomas;695
33.9;Optic Glioma;696
33.10;Craniopharyngiomas;698
33.11;Intracranial Germ Cell Tumors;699
33.12;Malignant Brain Tumors in Infants and Children Less than 3 Years of Age;700
33.13;Suggested Reading;701
34;Chapter 22. Neuroblastoma;702
34.1;Epidemiology;702
34.2;Predisposition;702
34.3;Pathology and Biology;702
34.4;Clinical Features;703
34.5;Neuroblastoma in the Neonate;706
34.6;Diagnosis and Staging;706
34.7;Prognosis and Risk Stratification;708
34.8;Treatment;710
34.9;Disease Stratification and Therapy;712
34.10;Post-Therapy Monitoring;721
34.11;Special Treatment Considerations;723
34.12;Neuroblastoma in the Adolescent and Young Adult;724
34.13;Suggested Reading;724
35;Chapter 23. Renal Tumors;726
35.1;Wilms' Tumor;726
35.2;Nephroblastomatosis;742
35.3;Congenital Mesoblastic Nephroma;742
35.4;Clear Cell Sarcoma of the Kidney;743
35.5;Rhabdoid Tumor of the Kidney;744
35.6;Renal Cell Carcinoma (RCC);744
35.7;Suggested Reading;744
36;Chapter 24. Rhabdomyosarcoma and Other Soft-Tissue Sarcomas;746
36.1;Incidence and Epidemiology;746
36.2;Pathologic Classification;749
36.3;Genetics;749
36.4;Clinical Features;750
36.5;Diagnostic Evaluation;752
36.6;Staging;753
36.7;Prognosis;756
36.8;Treatment;758
36.9;Follow-Up After Completion of Therapy;765
36.10;Recurrent Disease;766
36.11;Future Perspectives;767
36.12;Suggested Reading;768
37;Chapter 25. Malignant Bone Tumors;770
37.1;Osteosarcoma;770
37.2;Ewing Sarcoma;780
37.3;Suggested Reading;788
38;Chapter 26. Retinoblastoma;790
38.1;Incidence;790
38.2;Classification;790
38.3;Other Epidemiologic Data;793
38.4;Risk for Second Malignant Neoplasms (SMN);794
38.5;Pathology;794
38.6;Clinical Features;795
38.7;Diagnostic Procedures;796
38.8;Staging;797
38.9;Treatment;799
38.10;Post-Treatment Management;804
38.11;Future Perspectives;805
38.12;Suggested Reading;806
39;Chapter 27. Germ Cell Tumors;807
39.1;Incidence;807
39.2;Pathology;807
39.3;Clinical Features;808
39.4;Diagnostic Evaluation;812
39.5;Tumor Markers;813
39.6;Staging;814
39.7;Treatment;815
39.8;Relapsed and Resistant Germ Cell Tumors;824
39.9;Suggested Reading;825
40;Chapter 28. Hepatic Tumors;827
40.1;Incidence;827
40.2;Epidemiology;827
40.3;Pathology;828
40.4;Clinical Features;829
40.5;Diagnostic Evaluation;829
40.6;Staging;832
40.7;Treatment;832
40.8;Prognosis;835
40.9;Suggested Reading;836
41;Chapter 29. Hematopoietic Stem Cell Transplantation;837
41.1;Solid Tumors;840
41.2;Allogeneic Stem Cell Transplantation;841
41.3;Engraftment;850
41.4;Graft Versus Host Disease (GVHD);851
41.5;Autologous Stem Cell Transplantation;852
41.6;Complications of Hematopoietic Stem Cell Transplantation;854
41.7;Late Sequelae of Stem Cell Transplantation;866
41.8;Post-Stem Cell Transplantation Therapy;866
41.9;Suggested Reading;868
42;Chapter 30. Management of Oncologic Emergencies;870
42.1;Metabolic and Endocrine Emergencies;870
42.2;Oncologic Emergencies by Anatomic Region;879
42.3;Suggested Reading;887
43;Chapter 31. Supportive Care of Patients with Cancer;888
43.1;Management of Infectious Complications;888
43.2;Bacterial Infections;897
43.3;Fungal Infections;899
43.4;Viral Infections;905
43.5;Protozoan Infections;906
43.6;G-CSF and Granulocyte Infusions;907
43.7;Immunizations;907
43.8;Blood Component Therapy;909
43.9;Hematopoietic Growth Factors: Basic Biology of Growth Factors;917
43.10;Clinical use of G-CSF, GM-CSF, Erythropoietin and IL-11;919
43.11;Prevention of Organ Toxicity;923
43.12;Pain Management;927
43.13;General Guidelines for Management of Pain in Oncology Patients;933
43.14;Management of Nausea and Vomiting;935
43.15;Nutritional Support;944
43.16;Psychosocial Support and End-of-Life Care;949
43.17;Suggested Reading;949
44;Chapter 32. Evaluation, Investigations and Management of Late Effects of Childhood Cancer;952
44.1;Musculoskeletal Dysfunction;953
44.2;Cardiovascular Disorders;959
44.3;Respiratory System;961
44.4;Central Nervous System;964
44.5;Endocrine System;967
44.6;Genitourinary System;973
44.7;Ocular System;975
44.8;Auditory System;976
44.9;Gastrointestinal System;977
44.10;Immunologic System;977
44.11;Obesity;978
44.12;Second Malignant Neoplasms;978
44.13;Suggested Reading;981
45;Chapter 33. Psychosocial Aspects of Cancer for Children and their Families;983
45.1;Diagnosis;983
45.2;Treatment Initiation;989
45.3;Illness Stabilization;990
45.4;Relapses and Recurrences;991
45.5;Treatment Outcomes: The Unsuccessful Course;992
45.6;Treatment Outcomes: The Successful Course;995
45.7;Survivorship;995
45.8;Conclusion;997
45.9;Suggested Reading;997
46;Appendix 1 Hematological Reference Values;1000
46.1;Red Cell Values and Related Serum Values;1000
46.2;White Cell Values;1012
46.3;Platelet Values;1013
46.4;Coagulation Values;1014
46.5;Bone Marrow Cells;1022
47;Appendix 2 Biological Tumor Markers;1026
48;Appendix 3 Pharmacologic Properties of Commonly used Anticancer Drugs;1028
49;Index;1036
49.1;A;1036
49.2;B;1038
49.3;C;1039
49.4;D;1041
49.5;E;1042
49.6;F;1043
49.7;G;1043
49.8;H;1044
49.9;I;1047
49.10;J;1048
49.11;K;1048
49.12;L;1048
49.13;M;1049
49.14;N;1050
49.15;O;1051
49.16;P;1052
49.17;Q;1053
49.18;R;1053
49.19;S;1054
49.20;T;1055
49.21;U;1057
49.22;V;1057
49.23;W;1057
49.24;X;1058
49.25;Y;1058